Amirthalingam, G;
Bernal, JL;
Andrews, NJ;
Whitaker, H;
Gower, C;
Stowe, J;
Tessier, E;
Subbarao, S;
Ireland, G;
Baawuah, F;
et al.
Amirthalingam, G; Bernal, JL; Andrews, NJ; Whitaker, H; Gower, C; Stowe, J; Tessier, E; Subbarao, S; Ireland, G; Baawuah, F; Linley, E; Warrener, L; O'Brien, M; Whillock, C; Moss, P; Ladhani, SN; Brown, KE; Ramsay, ME
(2021)
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.
Nat Commun, 12 (1).
p. 7217.
ISSN 2041-1723
https://doi.org/10.1038/s41467-021-27410-5
SGUL Authors: Ladhani, Shamez Nizarali
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
|
|
PDF (Supplementary Information)
Published Version
Available under License Creative Commons Attribution. Download (176kB) | Preview |
|
|
PDF (Peer Review File)
Published Version
Available under License Creative Commons Attribution. Download (471kB) | Preview |
|
|
PDF (Reporting Summary)
Published Version
Available under License Creative Commons Attribution. Download (371kB) | Preview |
Abstract
The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50-89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14-35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65-84 days) compared with those vaccinated with a standard (19-29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14-35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with dose interval. Higher dose two VE was observed with >6 week interval between BNT162b2 doses compared to the standard schedule. Our findings suggest higher effectiveness against infection using an extended vaccine schedule. Given global vaccine constraints these results are relevant to policymakers.
Item Type: | Article | ||||||
---|---|---|---|---|---|---|---|
Additional Information: | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © Crown 2021 | ||||||
Keywords: | Aged, Aged, 80 and over, Antibodies, Viral, Antibody Formation, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, ChAdOx1 nCoV-19, England, Female, Humans, Immunization Schedule, Male, Middle Aged, Vaccine Efficacy, Humans, Antibodies, Viral, Immunization Schedule, Antibody Formation, Aged, Aged, 80 and over, Middle Aged, England, Female, Male, COVID-19, COVID-19 Vaccines, Vaccine Efficacy, BNT162 Vaccine, ChAdOx1 nCoV-19, MD Multidisciplinary | ||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||
Journal or Publication Title: | Nat Commun | ||||||
ISSN: | 2041-1723 | ||||||
Language: | eng | ||||||
Dates: |
|
||||||
Publisher License: | Creative Commons: Attribution 4.0 | ||||||
PubMed ID: | 34893611 | ||||||
Web of Science ID: | WOS:000729179400044 | ||||||
Go to PubMed abstract | |||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/114011 | ||||||
Publisher's version: | https://doi.org/10.1038/s41467-021-27410-5 |
Statistics
Actions (login required)
![]() |
Edit Item |